Valirx Share Discussion Threads

[base7] 06/12/2022 12:46

Lightweight RNS with no substance but compounds listed & only takes 1 or 2 to be taken to a higher level to demonstrate that we are undervalued.301 would be immense & we had probably all forgotten about Sepsis-2 major global health issues with,currently, no treatment at all.

[412069] 06/12/2022 09:35

And we still ain’t 4p Franco even off that rns.
Keep trying fella.

[sooty snipes] 06/12/2022 09:34

Pretty much everything that was said in the update was already known. Happy to hold but this fundraise must be the longest in history. Suzy Dilly should never have let it drag on for so long. Surely there must have been other candidates out there for 201. CLX 001 is the real jewel in the crown. If we were an American quoted company our share price would be much, much higher than this ridiculous low valuation

[francoismyname] 06/12/2022 08:27

Morning campers

[chesty1] 06/12/2022 08:27

801 and 401 this is a dog and will never fly! Pure spike stock…I would know I have picked many!

[qnq] 06/12/2022 08:18

typical small minded british investors mentality that are manipulated by market makers posting on here too.
this company is worth 100 pence a share as is and 250 pence once partner steps in.
triple negative cancer is a death senstejce and we valirx most likely have the drug.
Buy

[francoismyname] 06/12/2022 07:17

All jam tomorrow says the RNS.

Could show you 100 plus similar RNS’s over the past 12 years , all with jam tomorrow but always with no income coming in.

Cash burn continues unabated.

Only 7 months cash left as of today .

[412069] 02/12/2022 11:31

Why! we’re not even 4p Franco yet, what word will you use if we ever get that low.
Ho I know….unprecedented same as all the other snowflakes use.

[francoismyname] 02/12/2022 11:00

Looking dreadful here

[qnq] 02/12/2022 09:31

ignorance is a bliss.
luckily as UK hedge funds and even retail short these stocks large Pharma dont ignore the importance of the drug or peptides.
triple negative is a death sentence. data published back in July shows the potential.
partnership with king will make sure this company is well funded until 2999, yes.
a market cap thus low is a screaming acquisition and partnership a deal wilp be announced any minute.
the only mistake Suzy made is not moving company to the US. UK investors are destructive and cant hild on to their liquer.
but thanks to you guys my few thousand pounds will get me house on the beach with zero mortgage.
only fools will sell or short at this mcap.
conpany at current stage is at 95% discount.

[jasonpugh] 01/12/2022 22:51

Yo slater. You make me feel like a young paul newman you bullfrog you. Hows Cape town you spotted wart you? On a serious note. When is the best time to sell you beautiful constipated sloth 👍. Love you nick

[jasonpugh] 01/12/2022 10:22

Lol ben. Love your comment
Wheres adam Hargreaves our resident shareholder rep on lse? He normally comes on and reassures that everything is fine. Earth calling adam. 🤣

[francoismyname] 01/12/2022 09:55

People beginning to wake up and smell the coffee.

It’s laughable that a company that has delivered no income for 12 years, it’s latest attempt to try and get income in is delayed and on it’s arese after numerous delays of over a year , with a main product that’s been with a Japanese co for over 3 years with not ONE update in those 3 years, is still deemed investable.

Should fall hard from here . Cash burn continues unabated.

[ben gibbons] 01/12/2022 09:48

Thats 10p off francos target ;)

[jasonpugh] 01/12/2022 09:35

14p target. Lets go 👍

[412069] 01/12/2022 08:58

Clueless 4p Franco it’s being worked by someone both buying and selling to gain the best share price

[francoismyname] 01/12/2022 08:38

People selling in their droves

[jasonpugh] 30/11/2022 06:14

On the video presentation by suzy on Cytolytix she said two to three years before data could be utilised for further development. She is very excited by the science but this indicates a placing will be required for further evaluation
On val 201 she said she remains confident that theoromrx are the right partner for 201. However not on Theoremrx getting cash.
Conclusion. Cash will be needed and with the procrastinating theoromrx this investment in valirx is high risk short to medium term. Also why has adam Hargreaves on lse our shareholder representative gone quiet? DYOR

[412069] 29/11/2022 16:49

Finish it off Franc you still saying 4p placing are you ?